A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

QT Imaging Completes 1st In Class and 1st In Human Study: Quantitative Transmission Ultrasound Research Shows Better Performance than Mammography

January 5, 2021

QT Imaging, a developer of the FDA-cleared QTscan®, has completed a first-in-class and first-in-human study of transmission ultrasound as a new imaging technology for breast health screening.

The recently published study in Academic Radiology found that, compared to full-field digital mammography (FFDM), transmission ultrasound showed increased sensitivity, increased specificity, and lower recall rates.

1
Figure 4. Overall Performance Of The Radiologists As Measured In Terms Of Recall Rates For Qt And Ffdm. The Horizontal Axis Marks The Difference Between The Recall Rates Of Qt And Ffdm. A Lower Than Zero Value Indicates Qt Shows Improvement Over Ffdm; A Greater Than Zero Value Indicates Ffdm Shows Improvement Over Qt. Square (▪) Markers Correspond To Rrrc Results; Circle (•) Markers Correspond To Rrfc Results.

 

 

 

 

 

 

 

 

2
Figure 2. (A) Representative Speed-Of-Sound Image (Right) And The Corresponding Whole Breast H&Amp;E Section (Left) Showing Correlation Of Glandular And Ductal Histology With The Speed-Of-Sound Image

 

 

 

 

 

 

 

 

 

 

QT Imaging CEO and Chief Medical Officer Dr. John Klock advises, “This research represents an important milestone because it’s the first time a novel technology was compared to the standard of care in breast imaging in a primary breast cancer screening setting. While we are very encouraged by a 4% higher sensitivity, meaning the new modality can detect more lesions, the results of 16% higher specificity for transmission ultrasound is extremely promising. To have the ability to know if a lesion is problematic or not can be a game-changer, resulting in reduced callbacks, reduced biopsies, less anxiety for women, and perhaps even reduced healthcare costs.”

Transmission ultrasound is free of radiation, compression, and contrast injections, which makes it a safe, comfortable imaging experience for women of all ages. For younger women at high-risk for breast cancer, who do not qualify for x-ray mammography, it may provide a safer option that would allow them to have breast screening earlier and more often. QT Imaging will use this study, and additional ones, to secure FDA clearance for screening younger at-risk women under its FDA Breakthrough Device Designation.

While the published retrospective study shows that the inherently 3D nature of transmission ultrasound resulting in high resolution and high contrast-to-noise ratio makes it effective in evaluating breast tissue, a prospective study comparing true 3D transmission ultrasound to 3D breast tomosynthesis is warranted and will be published in the future. Based on learnings thus far, QT Imaging believes it is likely that transmission ultrasound will maintain its advantage in improved specificity and reduced callback rates.

Digital mammography has reduced mortality in the last couple of decades, but the industry now understands that interpreting mammographic images can be challenging in some scenarios, especially for women with extremely dense breasts. Advancements in the field will be welcomed by healthcare professionals, imaging experts, and the women they serve.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy